Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.46
    +2.34 (+0.31%)
     
  • GBP/EUR

    1.1672
    +0.0016 (+0.13%)
     
  • GBP/USD

    1.2477
    -0.0034 (-0.27%)
     
  • Bitcoin GBP

    50,891.70
    -579.31 (-1.13%)
     
  • CMC Crypto 200

    1,322.34
    -74.19 (-5.31%)
     
  • S&P 500

    5,099.52
    +51.10 (+1.01%)
     
  • DOW

    38,241.31
    +155.51 (+0.41%)
     
  • CRUDE OIL

    83.90
    +0.33 (+0.39%)
     
  • GOLD FUTURES

    2,347.60
    +5.10 (+0.22%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

Stocks pop as financials, industrials lead the way

The Dow is getting a boost here after the holiday-shortened week, with banks and industrials leading the way. Plus, Trump is hammering drugmakers — again. Is big pharma his next piñata to batter around? And, Twitter shares are getting dumped, but is Wall Street selling for the wrong reason? Plus, Nordstrom is opening new stores that sell … nothing. But customers are coming. Catch The Final Round at 3:55 ET p.m. with Jen Rogers, markets correspondent Myles Udland, and our Editor-in-Chief Andy Serwer.

Winners and losers

Stocks in the green include Boeing as it struck a deal to sell four Poseidon surveillance jets to the New Zealand government for $1.6 billion; GameStop, as Jefferies initiates coverage with a Buy rating and $18 price target claiming it’s on the way to transforming its business; and Groupon, with shares flying on a Recode report that it has contacted several public companies in the past month to try to drum up interest in acquiring it.

Stocks in the red include Procter & Gamble as Jefferies downgraded shares to Hold, with a lower $79 price target; CTI Biopharma, as the drugmaker’s experimental non-Hodgkin’s lymphoma treatment failed to meet its trial endpoint; and Twitter, with shares getting shellacked following a Washington Post report that it deleted more than 70 million accounts in May and June and that the pace of suspensions has continued this month.